The Nashville-based oncology management platform Thyme Care announced on Wednesday that it has successfully closed a $125 million Series E financing round, a significant milestone that elevates the company’s valuation to over $2 billion. This infusion of capital marks a pivotal moment for the four-year-old organization as it transitions from a specialized care navigation service into a diversified healthcare conglomerate under the newly formed parent entity, Thyme Companies. The move is designed to broaden the organization’s reach across the oncology continuum, addressing systemic inefficiencies in cancer treatment, drug procurement, and clinical research.
Led by Morgan Health—the healthcare arm of JPMorgan Chase—the funding round saw robust participation from a coalition of major industry players and venture capital firms. Key participants included Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. The breadth of this investor base, which includes some of the nation’s largest health insurers and strategic healthcare investors, underscores a growing industry-wide consensus on the necessity of value-based care models in the oncology sector.
A New Strategic Framework: The Launch of Thyme Companies
The most significant structural change accompanying the funding is the establishment of Thyme Companies. This new parent organization is tasked with building and managing a portfolio of independent oncology-focused businesses. The primary objective is to tackle the multifaceted challenges of the cancer care journey that extend beyond patient navigation. Specifically, the new entity will focus on accelerating the adoption of biosimilars—lower-cost alternatives to expensive biologic drugs—and increasing patient enrollment in clinical trials, which remains a chronic bottleneck in oncology innovation.
Robin Shah, a co-founder of Thyme Care, will transition into the role of Executive Chairman of Thyme Companies. In this capacity, Shah will spearhead long-term strategy and the development of new business units. Meanwhile, the core operations of Thyme Care will continue to be led by CEO Dr. Brad Diephuis, with co-founder Dr. Bobby Green maintaining his role as President and Chief Medical Officer. This leadership realignment ensures that while the organization expands into new verticals, the foundational care navigation business remains under experienced clinical and operational stewardship.
Chronology of Growth and Market Expansion
Since its inception in 2020, Thyme Care has undergone a rapid evolution. Founded by veterans of Flatiron Health and other prominent health-tech enterprises, the company was built on the premise that the current oncology system is too fragmented for patients to navigate alone.
By 2021, the company had established its first major partnerships with health plans, focusing on the Medicare Advantage population. By 2022 and 2023, Thyme Care aggressively expanded its geographic footprint, moving from a regional player to a national entity. Today, the company’s services are accessible to approximately 10.5 million individuals across all 50 U.S. states. The company has moved beyond simple navigation to becoming a full-service value-based care partner, taking on financial risk in collaboration with payers and providers to ensure high-quality outcomes at lower costs.
The Series E round follows a period of intense activity in the oncology space. As the Centers for Medicare & Medicaid Services (CMS) introduced the Enhancing Oncology Model (EOM) to succeed the Oncology Care Model (OCM), the demand for data-driven, patient-centric support systems skyrocketed. Thyme Care positioned itself as an essential intermediary, providing the technology and human capital necessary for oncology practices to succeed in these complex, risk-based reimbursement environments.
The Core Model: Enhancing the Patient and Provider Experience
At its heart, Thyme Care operates by integrating technology with a "human-in-the-loop" approach. The platform provides patients with access to a dedicated care team, including oncology nurses and resource specialists, who help coordinate appointments, manage side effects, and address social determinants of health (SDOH) such as transportation or food insecurity.
For providers, Thyme Care offers a suite of data insights that identify high-risk patients before they require emergency room visits. By intervening early—for instance, managing chemotherapy-induced nausea or dehydration at home or in the clinic rather than the hospital—the company reduces the total cost of care. This "inter-visit" care is often where the traditional fee-for-service model fails, as oncologists are typically only reimbursed for face-to-face encounters or drug administration. Thyme Care fills this gap, providing the continuous monitoring that value-based care requires.
Addressing the Economic Burden of Cancer Care
The economic implications of Thyme Care’s expansion are significant. Cancer care is one of the fastest-growing categories of healthcare spending in the United States, with costs projected to surpass $240 billion by 2030. A primary driver of these costs is the high price of specialty pharmaceuticals.
One of the first initiatives under the Thyme Companies umbrella will focus on the biosimilar market. Biosimilars are biological products that are highly similar to, and have no clinically meaningful differences from, an existing FDA-approved reference product. Despite their potential to save the U.S. healthcare system billions of dollars, adoption has been slow due to complex rebate structures and physician hesitancy. Thyme Companies aims to streamline the integration of these cost-effective therapies into clinical workflows, aligning financial incentives with lower-cost prescribing patterns.
Furthermore, the focus on clinical trials addresses a critical equity and innovation gap. Currently, fewer than 5% of adult cancer patients participate in clinical trials, often due to a lack of awareness or the logistical burdens of participation. By leveraging its 50-state reach and deep integration with community oncology practices, Thyme Care intends to democratize access to experimental therapies, potentially accelerating the time-to-market for life-saving drugs.
Official Responses and Strategic Vision
The investment from Morgan Health is particularly noteworthy, as it reflects a commitment from one of the world’s largest employers to find sustainable solutions for cancer care. Dan Mendelson, CEO of Morgan Health, emphasized the company’s track record in delivering tangible value. "People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs," Mendelson stated. He added that the investment is a vote of confidence in Thyme Care’s ability to navigate the "next wave of cancer care innovation."
Dr. Brad Diephuis, CEO of Thyme Care, noted that the capital would be used to fortify the existing value-based care business while providing the "runway" necessary for the parent company to innovate. "Our top priority is delivering for the members and partners we already serve, maintaining the high-value experience our members count on, and continuing to expand, including further into the commercial market," Diephuis told MedCity News. He highlighted that the core business is already profitable, allowing the new funding to be directed toward strategic diversification rather than merely sustaining operations.
Broader Implications for the Health Tech Industry
The rise of Thyme Care to a $2 billion valuation signifies a broader trend in the healthcare industry: the move toward specialized, disease-specific "platforms" that can manage the entire lifecycle of a condition. While generalist primary care platforms have seen significant investment over the last decade, the complexity of oncology requires a more nuanced approach.
Thyme Care’s success also highlights the shifting dynamics between payers and providers. By acting as a bridge, the company allows traditional oncology practices to participate in value-based arrangements without having to build their own massive data and navigation infrastructures. This "enablement" model is becoming the standard for managing high-cost chronic conditions.
However, Thyme Care is not alone in this space. The company faces competition from other emerging players like OncoveryCare and Maia Oncology, both of which are vying for market share in the oncology support sector. Additionally, established data giants and pharmacy benefit managers (PBMs) are increasingly looking to internalize navigation services. The creation of Thyme Companies is a defensive and offensive strategic move, allowing the organization to diversify its revenue streams and entrench itself deeper into the oncology supply chain.
Conclusion and Future Outlook
As Thyme Care prepares to launch the first business under Thyme Companies later this year, the industry will be watching closely to see if the organization can successfully replicate its navigation success in the areas of drug procurement and research. The transition from a service provider to a multi-faceted healthcare ecosystem represents a bold bet on the future of oncology—one where data, patient support, and financial alignment converge to make cancer treatment more manageable and affordable.
With $125 million in new capital and the backing of some of the most influential names in American healthcare, Thyme Care is well-positioned to lead the transition toward a more integrated oncology model. The focus on biosimilars and clinical trials suggests that the company is no longer content with just navigating the existing system; it intends to reshape the system itself. For the 10.5 million people currently covered by Thyme Care’s network, and the millions more who will likely follow, this evolution promises a future where the burden of coordinating cancer care no longer rests solely on the shoulders of the patient.
